Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep195 | Calcium and Bone | ECE2022

Management of denosumab discontinuation in a patient with osteonecrosis of the jaw and coexisting primary hyperparathyroidism

Malagrino Matteo , Belardinelli Elisabetta , Altieri Paola , Pagotto Uberto , Zavatta Guido

Context: Patients with primary hyperparathyroidism (PHPT) may be treated with denosumab due to coexisting osteoporosis. Few studies have been conducted in this population.Case presentation: An 84-year-old woman was seen in the outpatient clinic in March 2018 due to calcium levels at the upper limit of reference range (10,2 mg/dl) associated with elevated levels of PTH (112 pg/ml) and sufficient 25(OH)Vit D (24 ng/ml) levels, findings consistent with mild...

ea0081rc12.6 | Rapid Communications 12: Reproductive and Developmental Endocrinology | ECE2022

Is Turner syndrome at risk for thyroid carcinoma?

Belardinelli Elisabetta , Dionese Paola , Cecchetti Carolina , Vicennati Valentina , Repaci Andrea , Pagotto Uberto , Gambineri Alessandra

Background: Many questions concerning Turner Syndrome (TS) remain unresolved, such as the long-term complications and, therefore, the optimal care setting for adults. Most controversials regard tumors. Very few data are available on thyroid carcinoma and no specific screening protocol of monitoring is advised in the current official guidelines. This long-term cohort study was primarily aimed at estimating the incidence and time to comorbid conditions along the life course, inc...

ea0081p340 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Excellent disease control in Berardinelli Seip type 1 patient through dietary therapy alone: only an exception?

Cecchetti Carolina , Belardinelli Elisabetta , Dionese Paola , Teglia Rita , Di Cintio Ilaria , D'apice Maria Rosaria , Pagotto Uberto , Gambineri Alessandra

Background and Objective: Severe metabolic complications generally manifest at an early age in Berardinelli – Seip congenital lipodystrophy (BSCL) and their management is especially challenging, often requiring prompt pharmacological treatment with insulin-sensitizers, lipid lowering drugs, insulin and eventually metreleptin. Nutritional intervention with low lipid personalized diets is considered by experts a fundamental tool in handling the disease when associated with ...